Public Company News
Hanmi Signs Licensing Deal with Lilly for sonefpeglutide (LAPSGLP-2 analog)
Lilly licenses Hanmi's sonefpeglutide (LAPSGLP-2 analog) for multiple indications SEOUL, South Korea, May 31, 2026 /PRNewswire/ -- Hanmi Pharm. Co., Ltd. ("Hanmi")today announced that they have entered into a license agreement for the development, manufacturing and commercialization of Hanmi's b...
2026-06-01 11:09
5058
Supermicro Launches New Server Solutions with Intel Xeon 6+ Processors to Reduce TCO and Accelerate Time-to-Online for Large-Scale Cloud and Data Centers
* 12 new systems across Hyper, SuperBlade®, FlexTwin™, and GrandTwin® families offer industry-leading core density with up to 576 efficiency cores per server * Breakthrough performance-per-watt and energy efficiency designed to lower TCO and reduce power consumption in high-density cloud and ...
2026-06-01 11:00
7121
IEI Showcases Resilient Edge AI Platforms at COMPUTEX 2026: Advancing AI Deployment Across Industrial Applications
NEW TAIPEI CITY, June 1, 2026 /PRNewswire/ -- IEI Integration Corp.
2026-06-01 10:12
4202
Agoda and The Trade Desk Partner to Help Brands Reach High-Intent Travelers Across APAC
Collaboration enables advertisers to engage Agoda audiences before booking decisions are made SINGAPORE, June 1, 2026 /PRNewswire/ -- Digital travel platform, Agoda and global advertising technology leader, The Trade Desk (Nasdaq: TTD) today announced a strategic partnership to enable smarter tr...
2026-06-01 10:00
4402
Mahindra and Manulife Insurance JV Moves Ahead; Gets Approval from Ministry of Corporate Affairs
Entity to be called "Mahindra Manulife Insurance Limited"; a 50:50 partnership MUMBAI and HONG KONG, June 2, 2026 /PRNewswire/ -- Mahindra and Manulife announced their partnership to create a life insurance business on November 12, 2025. Both companies have confirmed the incorporation of the JV c...
2026-06-01 09:16
7669
Investor repositioning drives shift in Asia quant markets, BofA Securities conference shows
Key points * BofA Securities hosted its second annual Asia Pacific Integrated Quant Services Senior Leadership Conference in Hong Kong, convening more than 110 senior practitioners. * Discussions highlighted a shift in Asia's quant markets, with rising allocator interest, higher trading volu...
2026-06-01 09:15
4648
Hankook's Ventus Delivers Unwavering Performance Throughout WRC FORUM8 Rally Japan's Ever-Changing Conditions
* Round 7 of the 2026 WRC unfolded across the Aichi and Gifu regions of Japan, featuring fierce competition on rugged mountain stages * Ventus Z215 and Z210 rally tires delivered stable grip and consistent performance in rapidly changing road conditions * Round 8 of the 2026 WRC season, EKO ...
2026-06-01 09:10
5683
BofA Securities Asia Forum Gathers Global Investors Amid Surge in Hedge Funds Allocations
Key points * BofA Securities hosted its fourth annual Asia Alternatives Forum, bringing together more than 20 hedge fund managers and 120 institutional allocators. * Allocators of approximately $700 billion in hedge fund capital discussed market conditions and investment strategies. * A Bof...
2026-06-01 09:00
6941
UOB and FPT sign MoU to advance AI, technology transformation and financial innovation opportunities
SINGAPORE, June 1, 2026 /PRNewswire/ -- UOB and global technology corporation
FPT have signed a Memorandum of Understanding (MoU) to explore strategic
collaboration opportunities in artificial intelligence (AI), digital and
technology transformation, and financial services innovation.
2026-06-01 09:00
6451
Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting
SHANGHAI, May 31, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the long-term analysis results of satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product ca...
2026-06-01 08:15
5517
ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept
First-line NSCLC – Compelling Activity Across All PD-L1 Subgroups In first-line non-small cell lung cancer (NSCLC) patients with high PD-L1 expression (TPS ≥50%), CS2009 monotherapy achieved anobjective response rate (ORR) of 81.3% and a disease control rate (DCR) of 100.0%, with consistent benef...
2026-06-01 08:15
6305
MICROIP to Debut "AI Vehicle System Business Group" and Edge AI Innovations at COMPUTEX 2026
TAIPEI, June 1, 2026 /PRNewswire/ -- MICROIP (TPEx: 7796), specializing in AI software and ASIC design services, will unveil its "AI Vehicle System Business Group" at COMPUTEX 2026 (Booth A1215a, TWTC Hall 1, June 2-5). Echoing the "AI Together" theme, the showcase focuses on edge AI, smart mobil...
2026-06-01 08:00
5462
Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview
TAIPEI, June 1, 2026 /PRNewswire/ -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today highlighted a strategic vision detailed by its found...
2026-06-01 08:00
5000
2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
* IBI363 in combination with chemotherapy demonstrated encouraging efficacy signals and manageable safety in the first-line treatment of NSCLC with PD-L1 negative or low expression. The 3→1.5 mg/kg dose group (n=22) showed ORR of 86.4%, confirmed ORR (cORR) of 81.8% (95% CI: 59.7-94.8) and DCR ...
2026-06-01 08:00
5227
2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
* After long-term follow-up, IBI363 monotherapy demonstrated strong overall survival (OS) with a long tail effect in IO-resistant squamous NSCLC and adenoNSCLC * IBI363 has entered a global Phase 3 clinical study (MarsLight-11) for IO-resistant squamous NSCLC; pending regulatory communication...
2026-06-01 08:00
4991
HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session
CHICAGO, May 31, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that ivonescimab, the Company's first-in-class PD-1/VEGF bispecific antibody, has achieved a statistically significant and clinically meaningful improvement in overall survival (OS) as a first-l...
2026-05-31 21:00
4555
Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026
* Oral presentation of DZD6008 demonstrated strong and durable anti-tumor activity, excellent BBB-penetrant properties, and a favorable safety profile in patients relapsed from third-generation EGFR TKI * In treatment-naïve patients with advanced NSCLC without driver mutations, Golidocitinib,...
2026-05-31 08:09
6079
Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet
CHENGDU, China, May 31, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that the results of the Phase III clinical study OptiTROP-Lung05, evaluating the company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug con...
2026-05-31 08:00
8822
The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet
CHENGDU, China, May 30, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, the results of the Phase III clinical study OptiTROP-Lung05, evaluating...
2026-05-30 22:01
11448
Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO
CHENGDU, China, May 30, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced that at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA, results from the pivotal Phase II study of the Company's next-genera...
2026-05-30 21:51
10572
Week's Top Stories
Most Reposted
Hong Leong Bank Unveils HLB opus Extended Exclusively by Private Invitation
[Picked up by 317 media titles]
2026-09-03 23:53
Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
[Picked up by 312 media titles]
2026-09-02 12:17
Visa Launches Enhanced A2A Protect Innovations to Help Financial Institutions Stop Fraud Before Money Leaves Accounts
[Picked up by 311 media titles]
2026-09-02 08:30Klook Takes Creator Commerce Beyond Influence With Kreator Shops
[Picked up by 307 media titles]
2026-09-01 11:00
DayOne and TNB Explore Up To 1.5 GW of On-Site Power Generation to Advance Malaysia's Energy Resilience and Digital Economy
[Picked up by 292 media titles]
2026-09-01 17:36Most Read
Noah Holdings Limited Announces Changes to the Board and Board Committees
2026-08-29 04:30
7742